AXL and non-small cell lung carcinoma: More recently, a 2’-F-pyrimidine modified RNA aptamer targeting Axl receptor (GL21.T aptamer) has been used to selective deliver miR-212 into human non-small-cell lung carcinoma (NSCLC) Axl+ cells [62].